Impact of Discontinuing Dornase Alfa in People With CF on Highly Effective CFTR Modulator Therapy-A SIMPLIFY Sub-Study

NCT06350474 · clinicaltrials.gov ↗

NA

Phase

COMPLETED

Status

477

Enrollment

OTHER

Sponsor class

Conditions

Cystic Fibrosis

Interventions

OTHER: Discontinuation of dornase alfa (Dnase)
OTHER: Continuation of dornase alfa (Dnase)

Sponsor

Nicole Hamblett

Collaborators

[object Object]
[object Object]
[object Object]